Can Novo Nordisk bounce back?

17.01.2019 160 0 0 0

Açıklama

Shares in Novo Nordisk fell as much as 15 per cent after the US Food and Drug Administration withheld approval for its new insulin treatment pending further tests. With a quick approval previously priced into its stock, the decision came as a shock to the company. Lex's Julia Grindell and Vincent Boland consider whether the group's shares are now fairly priced, and the impact of the decision on this year's earnings.

Related Articles:
http://www.ft.com/intl/cms/s/0/4e55f55a-7422-11e2-a27c-00144feabdc0.html
http://www.ft.com/intl/cms/s/3/5fd083ca-7456-11e2-80a7-00144feabdc0.html

For more video content from the Financial Times, visit http://www.FT.com/video